Age and fast initial response predict omalizumab retreatment in chronic urticaria

Abstract

We found that omalizumab can be discontinued to reveal disease remission and avoid drug exposure in patients with chronic urticaria.Higher age and fast initial response predict the need for retreatment and can be used to counsel patients in clinical practice.